Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.

@article{Zhao2013SorafenibOS,
  title={Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.},
  author={Juping Zhao and Yu Zhu and Chongyu Zhang and Xiaojing Wang and Hongchao He and Haofei Wang and Yuxuan Wu and Wenlong Zhou and Zhoujun Shen},
  journal={Urologic oncology},
  year={2013},
  volume={31 8},
  pages={1800-5}
}
OBJECTIVE To evaluate the efficacy and safety of targeted agents (sorafenib and sunitinib) as postoperative adjuvant therapy in Chinese patients with clear cell renal cell carcinoma (CC-RCC) who are at high risk for disease recurrence. MATERIALS AND METHODS Forty-three patients treated at our center between December 2007 and December 2010 with locally advanced CC-RCC who were at a high risk for disease recurrence were enrolled into the study. The criteria for high risk of CC-RCC recurrence… CONTINUE READING
18 Citations
17 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Cancer statistics

  • A Jemal, R Siegel, J Xu
  • CA Cancer J Clin
  • 2010

Optimization of sunitinib therapy in metastatic renal cell carcinoma : Adverseevent management

  • S Négrier, A Ravaud
  • EJC Supplements
  • 2007

Similar Papers

Loading similar papers…